Biontech Se Share Price (NASDAQ: BNTX)

$111.45

▲

-1.1

(-0.98%)

Last updated on August 20, 2025 at 1:29 AM IST

$₹

Check the interactive Biontech Se Stock chart to analyse performance

Biontech Se stock performance

as on August 20, 2025 at 1:29 AM IST

Today's Low:$111.45
Today's High:$114.01
$111.45
0.0%
Downside
Day's Volatility :2.25%
Upside
2.25%
52 Weeks Low:$81.20
52 Weeks High:$131.49
$111.45
27.14%
Downside
52 Weeks Volatility :38.25%
Upside
15.24%

Biontech Se Stock Returns

Period	Biontech Se	Sector (Health Care)	Index (Russel 2000)
3 Months	12.47%	1.5%	0.0%
6 Months	-6.8%	-7.1%	0.0%
1 Year	25.89%	-11.4%	0.0%
3 Years	-24.85%	2.9%	-9.6%

Biontech Se Key Stats

Check Biontech Se key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$112.55
Open	$113.38
Today's High	$114.01
Today's Low	$111.45
Market Capitalization	$27.1B
Today's Volume	$546.7K
52 Week High	$131.49
52 Week Low	$81.2
Revenue TTM	$2.9B
EBITDA	$-493.7M
Earnings Per Share (EPS)	$-1.68
Profit Margin	-11.98%
Quarterly Earnings Growth YOY	-0.43%
Return On Equity TTM	-1.84%

Stock Returns calculator for Biontech Se Stock including INR - Dollar returns

The Biontech Se stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Biontech Se investment value today

Current value as on today

₹1,29,678

Returns

₹29,678

(+29.68%)

Returns from Biontech Se Stock

₹25,890 (+25.89%)

Dollar Returns*

₹3,788 (+3.79%)

Indian investors sentiment towards Biontech Se Stock

15%

Period: Jul 20, 2025 to Aug 19, 2025. Change in 30 Days versus previous period

Search interest for Biontech Se Stock from India on INDmoney has increased by 15% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Biontech Se

Name
Holdings %
Name
Holdings %
Baillie Gifford & Co Limited.
3.34%
FMR Inc
3.03%
Flossbach von Storch AG
1.76%
PRIMECAP Management Company
1.66%
Pfizer Inc
1.52%
T. Rowe Price Investment Management,Inc.
1.50%

Analyst Recommendation on Biontech Se Stock

Rating

Trend

Buy

54%Buy

37%Hold

8%Sell

Based on 24 Wall street analysts offering stock ratings for Biontech Se(by analysts ranked 0 to 5 stars)

Biontech Se Share Price Target

What analysts predicted

Upside of 23.68%

Target:

$137.84

Current:

$111.45

Biontech Se share price target is $137.84, a slight Upside of 23.68% compared to current price of $111.45 as per analysts' prediction.

Biontech Se Stock Insights

Price Movement
In the last 1 year, BNTX stock has moved up by 25.9%
Increasing Revenue
Biontech SE has shown strong performance in its revenue over the last two quarters. Revenue increased from $182.8 million to $260.8 million, indicating an average growth of 29.9% per quarter.
Increasing Net Profit
BioNTech SE has shown an improvement in its net profit over the last two quarters. The net profit increased from -$415.8 million to -$386.6 million, reflecting an average increase of 7.6% per quarter.
BNTX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 37.4%
BNTX vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.3% return, outperforming this stock by 137.0%
Price to Sales
Biontech SE currently has a Price-to-Sales (P/S) ratio of 9.3, meaning investors are willing to pay $9.3 for every $1 of sales the company generates. In comparison, Alnylam Pharmaceuticals, Inc. has a higher P/S ratio of 24.1, indicating that investors are paying more for each dollar of sales from that company.

Biontech Se Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$120.7M	↓ 14.88%
Net Income	$-199.1M	↑ 273.13%
Net Profit Margin	-165.0%	↓ 127.36%

	FY20	Y/Y Change
Revenue	$586.7M	↑ 344.17%
Net Income	$18.5M	↓ 108.48%
Net Profit Margin	3.15%	↑ 168.15%

	FY21	Y/Y Change
Revenue	$21.5B	↑ 3834.42%
Net Income	$11.6B	↑ 67613.82%
Net Profit Margin	54.24%	↑ 51.09%

	FY22	Y/Y Change
Revenue	$18.3B	↓ 8.78%
Net Income	$10.0B	↓ 8.34%
Net Profit Margin	54.5%	↑ 0.26%

	FY23	Y/Y Change
Revenue	$4.2B	↓ 77.94%
Net Income	$1.0B	↓ 90.14%
Net Profit Margin	24.36%	↓ 30.14%

	FY24	Y/Y Change
Revenue	$2.9B	↓ 27.96%
Net Income	$-696.1M	↓ 171.51%
Net Profit Margin	-24.18%	↓ 48.54%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$205.1M	↓ 87.24%
Net Income	$-342.5M	↓ 168.81%
Net Profit Margin	-166.98%	↓ 197.94%

	Q2 FY24	Q/Q Change
Revenue	$139.2M	↓ 31.45%
Net Income	$-873.6M	↑ 157.66%
Net Profit Margin	-627.66%	↓ 460.68%

	Q3 FY24	Q/Q Change
Revenue	$1.4B	↑ 849.5%
Net Income	$217.0M	↓ 124.07%
Net Profit Margin	15.91%	↑ 643.57%

	Q4 FY24	Q/Q Change
Revenue	$1.2B	↓ 3.11%
Net Income	$271.5M	↑ 32.77%
Net Profit Margin	21.81%	↑ 5.9%

	Q1 FY25	Q/Q Change
Revenue	$197.7M	↓ 84.64%
Net Income	$-449.7M	↓ 260.23%
Net Profit Margin	-227.46%	↓ 249.27%

	Q2 FY25	Q/Q Change
Revenue	$260.8M	↑ 42.67%
Net Income	$-386.6M	↓ 7.02%
Net Profit Margin	-148.24%	↑ 79.22%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-150.3M	↑ 363.86%

	FY20	Y/Y Change
Profit	$-270.1M	↑ 64.18%

	FY21	Y/Y Change
Profit	$17.1B	↓ 6907.87%

	FY22	Y/Y Change
Profit	$13.5B	↓ 15.46%

	FY23	Y/Y Change
Profit	$3.5B	↓ 74.81%

	FY24	Y/Y Change
Profit	$2.3B	↓ 31.36%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$140.5M	↓ 90.06%

	Q2 FY24	Q/Q Change
Profit	$74.5M	↓ 46.43%

	Q3 FY24	Q/Q Change
Profit	$1.2B	↑ 1418.69%

	Q4 FY24	Q/Q Change
Profit	$990.3M	↓ 10.0%

	Q1 FY25	Q/Q Change
Profit	$107.1M	↓ 89.54%

	Q2 FY25	Q/Q Change
Profit	$184.4M	↑ 86.26%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-220.6M	↑ 241.25%
Investing Cash Flow	$-85.7M	↑ 14.84%
Financing Cash Flow	$425.9M	↑ 4.96%

	FY20	Y/Y Change
Operating Cash Flow	$-16.4M	↓ 93.21%
Investing Cash Flow	$-176.2M	↑ 87.83%
Financing Cash Flow	$1.1B	↑ 133.43%

	FY21	Y/Y Change
Operating Cash Flow	$1.0B	↓ 6703.09%
Investing Cash Flow	$-640.0M	↑ 290.82%
Financing Cash Flow	$106.5M	↓ 89.47%

	FY22	Y/Y Change
Operating Cash Flow	$14.4B	↑ 1426.06%
Investing Cash Flow	$-37.4M	↓ 93.76%
Financing Cash Flow	$-1.5B	↓ 1606.69%

	FY23	Y/Y Change
Operating Cash Flow	$5.9B	↓ 60.44%
Investing Cash Flow	$-7.6B	↑ 19601.13%
Financing Cash Flow	$-849.4M	↓ 45.14%

	FY24	Y/Y Change
Operating Cash Flow	$217.3M	↓ 96.13%
Investing Cash Flow	$-2.2B	↓ 70.07%
Financing Cash Flow	$-48.0M	↓ 94.1%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-346.9M	↓ 137.51%
Investing Cash Flow	$-2.5B	↓ 13.99%
Financing Cash Flow	$-8.5M	↓ 39.18%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$1.8B	↓ 614.62%
Investing Cash Flow	$-250.0M	↓ 89.98%
Financing Cash Flow	$-24.8M	↑ 193.86%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-686.0M	↓ 137.61%
Investing Cash Flow	$-157.8M	↓ 38.83%
Financing Cash Flow	$-8.8M	↓ 65.74%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-506.5M	↓ 21.63%
Investing Cash Flow	$634.7M	↓ 526.95%
Financing Cash Flow	$-7.6M	↓ 7.59%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-844.3M	↑ 61.25%
Investing Cash Flow	$1.3B	↑ 105.51%
Financing Cash Flow	$-14.9M	↑ 89.04%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$146.5M	↓ 118.77%
Investing Cash Flow	$-64.4M	↓ 105.17%
Financing Cash Flow	$-13.3M	↓ 3.62%

Biontech Se Technicals Summary

Sell

Neutral

Buy

Biontech Se is currently in a neutral trading position according to technical analysis indicators.

Biontech Se Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Biontech Se	2.33%	-6.8%	25.89%	-24.85%	52.63%
Regeneron Pharmaceuticals, Inc.	4.65%	-16.73%	-52.11%	-6.73%	-5.71%
Beone Medicines Ltd	7.16%	32.17%	61.08%	80.84%	30.07%
Vertex Pharmaceuticals Incorporated	-14.79%	-17.19%	-19.84%	32.96%	44.01%
Alnylam Pharmaceuticals, Inc.	43.03%	83.01%	63.29%	110.39%	235.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Biontech Se	160.8	NA	0.04	-4.19	-0.02	-0.02	NA	76.98
Regeneron Pharmaceuticals, Inc.	14.47	14.47	1.18	39.36	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.73	27.73	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Biontech Se	Buy	$27.1B	52.63%	160.8	-11.98%
Regeneron Pharmaceuticals, Inc.	Buy	$60.8B	-5.71%	14.47	31.37%
Beone Medicines Ltd	NA	$39.3B	30.07%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.0B	44.01%	27.73	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.8B	235.62%	NA	-12.96%

Biontech Se Dividend announcements

Biontech Se Dividends June, 2022
In the quarter ending June,2022. Biontech Se has declared dividend of $2.11

About Biontech Se

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Organization	Biontech Se
Employees	6772
CEO	Dr. Ugur Sahin M.D.
Industry	Health Technology

Key Management of Biontech Se

Name	Title
Dr. Ugur Sahin M.D.	Co-Founder, CEO & Chair of the Management Board
Dr. Ozlem Tureci M.D.	Co-Founder, Chief Medical Officer & Member of Management Board
Dr. Sierk Poetting Ph.D.	MD, COO & Member of Management Board
Mr. Ryan Richardson	Chief Strategy Officer, MD & Member of Management Board
Dr. James Timothy Patrick Ryan Ph.D.	Chief Legal & Business Officer & Member of the Management Board
Ms. Annemarie Hanekamp	Chief Commercial Officer & Member of Management Board
Mr. Ramón Zapata-Gomez	CFO & Member of Management Board
Ms. Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting
Ms. Beate Berns	Senior Vice President of Global Human Resources
Dr. Oliver Henning Ph.D.	Senior Vice President of Operations

Important FAQs about investing in BNTX Stock from India :

What is Biontech Se share price today?

Biontech Se share price today is $111.45 as on August 20, 2025 at 1:29 AM IST at the close of the market. Biontech Se share today touched a day high of $114.01 and a low of $111.45.

What is the 52 week high and 52 week low for Biontech Se share?

Biontech Se share touched a 52 week high of $131.49 and a 52 week low of $81.20. Biontech Se stock price today i.e. August 20, 2025 at 1:29 AM IST is closed at $111.45, lower by 15.24% versus the 52 week high.

How to invest in Biontech Se Stock (BNTX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Biontech Se on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biontech Se Shares that will get you 0.0135 shares as per Biontech Se share price of $111.45 per share as on August 20, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Biontech Se Stock (BNTX) from India?

Indian investors can start investing in Biontech Se (BNTX) shares with as little as ₹86.938 or $1 (as of August 20, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹869.38 in Biontech Se stock (as per the Rupee-Dollar exchange rate as on August 20, 2025). Based on Biontech Se share’s latest price of $111.45 as on August 20, 2025 at 1:29 AM IST, you will get 0.0897 shares of Biontech Se. Learn more about fractional shares .

What are the returns that Biontech Se has given to Indian investors in the last 5 years?

Biontech Se stock has given 52.63% share price returns and 16.15% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?